Olanzapine (Zyprexa Relprevv) vs Perseris
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (Zyprexa Relprevv)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00088478 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.
Reported efficacy
Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)
Result source: NCT00088478
Perseris
Rights held by Indivior Pharmaceuticals, Inc.; US product discontinued
NCT02109562 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 354 participants and a clinical primary endpoint measuring change in PANSS total score. The primary endpoint was met for both RBP-7000 doses: PANSS scores improved significantly more than with placebo.
Reported efficacy
Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): RBP-7000 90 mg -15.367 units on a scale (Standard Error 1.223) | RBP-7000 120 mg -16.456 units on a scale (Standard Error 1.2073) vs Placebo -9.219 units on a scale (Standard Error 1.2162) (met)
Result source: NCT02109562
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Olanzapine (Zyprexa Relprevv) | Perseris |
|---|---|---|
| PANSS total, change | —Not posted · NCT00088491 | -16.5 vs -9.2−7.2 vs placeboNCT021095627 other results
|
| CGI-S, change | -0.4 vs -0.3vs Oral OlanzapineNCT00320489 | -0.1 vs -0.3+0.2 vs placeboNCT022038387 other results
|
| PANSS response | —Not posted · NCT00088491 | —Not reported |
| PSP, change | —Not posted · NCT00088491 | —Not reported |
| Relapse (% of patients) | 20.1% vs 18.5%vs Oral OlanzapineNCT00320489 | —Not reported |
PANSS total, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Perseris
- -16.5 vs -9.2−7.2 vs placeboNCT02109562
7 other results
- -15.4 vs -9.2 NCT02109562
- -1.2 vs -8.2 NCT02203838
- -1.2 vs -4.8 NCT02203838
- -9.4 vs -8.2 NCT02203838
- -2.4 vs -4.8 NCT02203838
- -10 vs -8.2 NCT02203838
- -8.3 vs -4.8 NCT02203838
CGI-S, change
- Olanzapine (Zyprexa Relprevv)
- -0.4 vs -0.3vs Oral OlanzapineNCT00320489
- Perseris
- -0.1 vs -0.3+0.2 vs placeboNCT02203838
7 other results
- 0 vs -0.3 NCT02203838
- -0.9 vs -0.5 NCT02109562
- -0.9 vs -0.5 NCT02109562
- -0.4 vs -0.3 NCT02203838
- -0.1 vs -0.3 NCT02203838
- -0.3 vs -0.3 NCT02203838
- -0.2 vs -0.3 NCT02203838
PANSS response
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Perseris
- —Not reported
PSP, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Perseris
- —Not reported
Relapse (% of patients)
- Olanzapine (Zyprexa Relprevv)
- 20.1% vs 18.5%vs Oral OlanzapineNCT00320489
- Perseris
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Olanzapine (Zyprexa Relprevv): 4 of 4 rows · Perseris: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olanzapine (Zyprexa Relprevv) | Perseris |
|---|---|---|
| Dropout rate | 54.9%a NCT00320489 · Phase 3 · monotherapy show 1 more result60.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 28.6%120 mgb NCT02109562 · Phase 3 · combination show 8 more results22.4%90 mg NCT02109562 · Phase 3 · combination 54.5%120 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 51.6%90 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 51.5%De Novo Participants NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 78.3%180 mg subcutaneous NCT03978832 · Phase 4 · registry result, not featured evidence 40%120 mg NCT01677377 · Phase 2 · registry result, not featured evidence 6.7%90 mg NCT01677377 · Phase 2 · registry result, not featured evidence 6.7%60 mg NCT01677377 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 9.8%a NCT00320489 · Phase 3 · monotherapy show 1 more result8.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 1.7%120 mgb NCT02109562 · Phase 3 · combination show 8 more results0%90 mg NCT02109562 · Phase 3 · combination 6.1%120 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 9.7%90 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 11.3%De Novo Participants NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 1.4%180 mg subcutaneous NCT03978832 · Phase 4 · registry result, not featured evidence —120 mg NCT01677377 · Phase 2 · registry result, not featured evidence —90 mg NCT01677377 · Phase 2 · registry result, not featured evidence —60 mg NCT01677377 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 9.5%a NCT00320489 · Phase 3 · monotherapy show 1 more result18.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 0.9%120 mgb NCT02109562 · Phase 3 · combination show 8 more results0%90 mg NCT02109562 · Phase 3 · combination 9.1%120 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 9.7%90 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 6.1%De Novo Participants NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 4.3%180 mg subcutaneous NCT03978832 · Phase 4 · registry result, not featured evidence 6.7%120 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%90 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%60 mg NCT01677377 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 1 more resultweight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence | 120 mgb injection site pain 22.2% (placebo 19.5%) headache 15.4% (placebo 23.7%) weight increased 12.8% (placebo 3.4%) NCT02109562 · Phase 3 · combination show 8 more results90 mg headache 17.4% (placebo 23.7%) injection site pain 15.7% (placebo 19.5%) weight increased 13% (placebo 3.4%) NCT02109562 · Phase 3 · combination 120 mg injection site pain 21.2% (placebo 7.1%) injection site induration 9.1% (placebo 0%) injection site nodule 9.1% (placebo 3.6%) NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 90 mg headache 12.9% (placebo 0%) injection site pain 12.9% (placebo 7.1%) insomnia 12.9% (placebo 3.6%) NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 weight increased 14.7% (placebo 3.6%) injection site pain 12.7% (placebo 7.1%) injection site nodule 7.1% (placebo 3.6%) NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 180 mg subcutaneous upper respiratory tract infection 13% blood prolactin increased 8.7% decreased appetite 8.7% NCT03978832 · Phase 4 · registry result, not featured evidence 120 mg cough 20% dyspepsia 20% weight increased 20% NCT01677377 · Phase 2 · registry result, not featured evidence 90 mg weight increased 33.3% headache 20% dyspepsia 13.3% NCT01677377 · Phase 2 · registry result, not featured evidence 60 mg weight increased 26.7% headache 20% rash 20% NCT01677377 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olanzapine (Zyprexa Relprevv)
+ 14 further endpoints in the CSV export.
Perseris
show 7 more results
show 2 more results
show 2 more results
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Perseris's landscape